Duopharma Biotech Bhd (DPHARMA.KL) Stock Price

Duopharma Biotech Bhd Price

Bursa Malaysia·CLOSED
1.10
​
Market closed

Over the last 19 years Duopharma Biotech Bhd grew revenue by 12.0% annually, reaching 813.70 M MYR. Earnings per share have grown at 0.8% per year over the last 19 years. For Duopharma Biotech Bhd, the net margin of 7.7% is down versus 10.3% a few years ago. At today's price the dividend yield works out to roughly 2.55%. The payout ratio is around 43% of earnings. The dividend has grown at 2.0% per year over the past 19 years. The consensus 12-month price target for Duopharma Biotech Bhd is 1.73 MYR, about 57.6% above where the stock trades today. Of 11 analysts, 10 rate the stock a buy — an overall Buy consensus.

Duopharma Biotech Bhd stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Duopharma Biotech Bhd business model & stock analysis

Duopharma Biotech Bhd generates revenue through its three business segments: Consumer Healthcare (CHC), Ethical Classic Business (ECB), and Ethical Specialty Business (ESB). The CHC segment sells over-the-counter products like vitamins, supplements, analgesics, eyecare, and antacids under brands such as Flavettes, CHAMPS, Uphamol, and Eye Glo to domestic, regional, and international markets. The ECB segment produces over 300 generic drugs including Crystorvas, Prelica, and Omesec, targeting healthcare providers and pharmacies. The ESB segment focuses on specialized drugs, medical devices, and consumables, while also commercializing biosimilars like ERYSAA, Basalog One, and Zuhera through international partnerships. The company's products are distributed across multiple markets, with CHC brands reaching consumers directly through retail channels. ECB drugs are supplied to healthcare institutions and pharmacies, while ESB products target specialized medical needs. Biosimilar collaborations with international partners enable the company to expand its portfolio beyond traditional pharmaceuticals, enhancing its market presence in both domestic and global segments. Duopharma Biotech Bhd's revenue streams are diversified across consumer-facing CHC products, generic ECB drugs, and specialized ESB solutions. The company leverages its established brands and partnerships to serve both mass-market and niche healthcare segments, ensuring steady demand for its pharmaceutical offerings in Malaysia and beyond.

Frequently asked questions about Duopharma Biotech Bhd

Analysts currently set an average price target of 1.72 MYR for the Duopharma Biotech Bhd stock (median: 1.73 MYR), implying +56.3 % versus the latest price. The consensus is based on 11 analyst ratings.

11 analysts currently rate the Duopharma Biotech Bhd stock: 10 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Duopharma Biotech Bhd to generate revenue of 1.02 B MYR and earnings per share of 0.11 MYR.

Converted at the current exchange rate, the Duopharma Biotech Bhd share trades at 0.24 EUR (1.10 MYR).

The expected revenue of Duopharma Biotech Bhd is 1.02 B MYR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Duopharma Biotech Bhd is 103.61 M MYR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Duopharma Biotech Bhd is currently 10.21. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Duopharma Biotech Bhd stock.

The price-to-sales ratio (P/S) of Duopharma Biotech Bhd is currently 1.04. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Duopharma Biotech Bhd stock.

The Eulerpool Quality Score for Duopharma Biotech Bhd is 7/10.

The ISIN of Duopharma Biotech Bhd is MYL7148OO009. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Duopharma Biotech Bhd is DPHARMA.KL. The ticker symbol is used to trade Duopharma Biotech Bhd shares on the stock exchange.

Fair ValueTerminal
0.95 MYR
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
538,158.07 MYR
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Malaysia
Currency
MYR
Initial public offering
Jul 18, 2002
ISIN
MYL7148OO009
Cusip
Y2154H105
Market capitalization
1.06 B MYRSmall Cap
52-Week Range
PEG
3.44
P/E ratio
P/Ee 2025
11.09
P/Ee 2026
10.21
P/Ee 2027
9.61
P/S
P/Se
1.12
EV/EBIT
13.30
P/B Ratio
1.49
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
5.13 %
Dividend
Dividend yield
2.55 %
Est. Dividend Yield
3.18 %
Payout Ratio
43.01 %
Dividend growth Ø5Y
-6.43 %
Dividend payments per year
2
Dividend paid since
23 years
Dividend not reduced since
3 years
Dividend increased since
2 years
Dividend withholding tax
0.00 %
Last updated Nov 18, 2026, 7:16 AM

Duopharma Biotech Bhd Peer Group

Duopharma Biotech Bhd Ticker

KLS · 7148.KL

Duopharma Biotech Bhd FIGI

DBB:MK · BBG000N9YML5